Using Deferoxamine to treat Aneurysmal Subarachnoid Hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of deferoxamine mesylate in patients with aneurysmal subarachnoid hemorrhage (aSAH). Participants will be randomly assigned to receive either deferoxamine or a placebo within 24 hours of symptom onset. The study aims to assess the impact of deferoxamine on reducing complications associated with iron release, such as cerebral edema and ischemia. Patient outcomes will be monitored for up to six months post-discharge to determine the treatment's effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aneurysmal SAH confirmed with vascular imaging
* Aneurysm treated with endovascular or microsurgical intervention
* Hunt-Hess ≤ 4
* Modified Fisher Grade I-IV
* Glasgow Coma Scale (GCS) ≥ 7 following External Ventricular Drain (EVD) placement if indicated
* First dose of drug can be administered within 24 hours of symptom onset
* Functional independence prior to SAH, Modified Rankin Scale (mRS) ≤ 1
* Informed consent obtained by patient or legal authorized representative (LAR)

Exclusion Criteria:

* Previous hypersensitivity to or treatment with deferoxamine
* Presence of giant aneurysm (\>25 mm in size)
* Known severe iron deficiency anemia, Hemoglobin (Hgb) g/dl ≤ 7 or transfusion dependent
* Irreversibly impaired brainstem function
* Abnormal renal function, Serum Creatinine\> 2 mg/dL
* Pre-existing severe disability, mRS ≥ 2
* Coagulopathy, including use of anti-platelet or anticoagulant drugs
* Known severe hearing loss
* Chronic pulmonary disease that limits basic activities of daily living at baseline, or requires the use of home oxygen.
* Acute pulmonary disease with the need for any of the following - in a 72 hour period prior to enrollment: \>4L/minute nasal cannula (or equivalent O2 delivery via face mask/ tent), heated-high flow nasal cannula, noninvasive positive pressure ventilation, and in intubated patients FiO2\>45% or positive end-expiratory pressure (PEEP) \> 8cmH2O. This does not include the use of supplemental oxygen in any form for pre-oxygenation, apneic oxygenation, or peri-procedural support alone.
* Taking iron supplements containing \> 325 mg of ferrous iron
* Pregnancy or nursing
* Life expectancy less than 90 days due to co-morbidities
* Concurrent participation in another research protocol for investigation of another experimental therapy, though observational studies are allowed
* Prior history of hepatic dysfunction
* Known cytopenia (platelets \< 50,000, Absolute neutrophil count \< 500)
* Current use of prochlorperazine
* History of severe psychiatric disorder

Where it's running

• University of Michigan
  Ann Arbor, Michigan, United States Recruiting

Study contacts

• Principal investigator: Aditya Pandey, MD — University of Michigan
• Study coordinator: Sravanthi Koduri
• Email: skoduri@med.umich.edu
• Phone: 734-647-7960

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nitric Oxide Use to Predict Vasospasm in Aneurysmal Subarachnoid Hemorrhage

  This study tests whether nitric oxide consumption in CSF can predict cerebral vasospasm in patients with aneurysmal SAH.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07614906

• Multi-omics program to understand complications and outcomes after aneurysmal subarachnoid hemorrhage

  This project will test if combining blood, cerebrospinal fluid, urine, imaging, and multi-omics data can find biomarkers that predict complications and outcomes in adults with aneurysmal subarachnoid hemorrhage.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07270419

• Dome-only coiling for severe aneurysmal subarachnoid hemorrhage

  This will test a minimally invasive dome-protection coiling procedure to prevent re-bleeding in adults who have had a severe aneurysmal subarachnoid hemorrhage.

  Recruiting University of Louisville · Louisville, Kentucky · NCT07250958

• Cilostazol to help prevent delayed brain ischemia after aneurysm bleed

  This study tests whether cilostazol can reduce delayed brain ischemia and improve outcomes after aneurysmal subarachnoid hemorrhage in adults who had recent aneurysm treatment.

  Recruiting Phase 3 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07249853

• Transcutaneous Vagal Nerve Stimulation to help with brain vessel narrowing after aneurysm rupture

  This trial tests whether using a noninvasive nerve stimulation device can reduce cerebral vasospasm after an aneurysmal brain bleed in adults 18–65 who are undergoing standard treatment.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07131696

• Tocilizumab-aazg to reduce stroke risk after a ruptured brain aneurysm

  This trial will try to see if a single IV dose of tocilizumab-aazg is safe and can help prevent delayed strokes in adults who have had a ruptured brain aneurysm (aneurysmal subarachnoid hemorrhage).

  Recruiting Phase 1 University of Florida · Gainesville, Florida · NCT06863480

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.